SINGAPORE: In a bid to bolster Singapore’s healthcare resilience, the country has launched Asia’s first fully automated mRNA production facility.
The new biofactory, capable of rapidly manufacturing vaccines and other critical treatments, will support Singapore’s response to health crises and advance local production of therapies for cancer and genetic diseases.
With cutting-edge automation, the facility can produce mRNA material for up to 100,000 doses of a COVID-19 vaccine daily, positioning Singapore to act decisively in future public health emergencies. The versatility of mRNA technology means that the facility’s output can be quickly adapted to address different viral threats, providing a robust defence against evolving pathogens.Singapore has already invested around $97 million to cement its role as a leader in nucleic acid drug therapy, focusing on both research and commercialization.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Singapore leads Asia-Pacific in life sciences investments in 2024 Singapore News%
Read more »
Singapore shares rose on Tuesday’s open—STI edged up 0.1% Singapore News%
Read more »
Singapore ranked fourth richest nation in the world Singapore News%
Read more »
Singapore sets ambitious target for net zero emissions by 2050 Singapore News%
Read more »
Singapore stocks rose on Wednesday’s open—STI gained 0.2% Singapore News%
Read more »
Hong Kong reclaims title as World’s Freest Economy, overtaking Singapore Singapore News%
Read more »